Pharma manager bets on post-vaccine hike in routine health appointments

While active health care investor Fondita banks on medical needs in the post-Covid-19 world, the first portfolio review after the pandemic's onset will be carried out in December at Seligson's passively managed pharmaceutical fund. "We are trying to interpret what will happen in the markets after there is a vaccination," Fondita's CEO says.

Photo: Pexels

Following a go-ahead from safety watchdogs to resume clinical trials for a Covid-19 vaccine candidate on Sunday, the share price of British-Swedish drugmaker AstraZeneca has experienced steady increase since Monday. The same day Pfizer announced it is likely the US will deploy a Covid-19 shot before the end of the year.

At Finnish asset manager Seligson, some 3.57 percent of the company's Global Top 25 Pharmaceutical funds and Fondita’s Healthcare fund 3.6 percent of portfolio is invested in AstraZeneca.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from AMWatch

ATP's managed assets maintained growth in Q3

A positive result from investments and a negative hedging portfolio outcome are the main takeaways from ATP's Q3 report, which reports that total managed assets have increased, and the bonus rate has also swelled further.

Velliv divests coal and tar sands

Neither coal nor oil extracted from tar sands will be be found in Velliv's portfolio now that the company has decided to completely exclude companies associated with those activites.

Further reading

Related articles

Trial banner

Latest news


Latest news from FinansWatch (dk)

Latest news from EnergyWatch

Latest news from ShippingWatch